Bronchoscopy Screening for High-risk Population of Lung Cancer With Severe Smoking With Negative LDCT Screen

Heavy Smoking Clinical Trial

Official title: Bronchoscopy Screening of High-risk Population of Lung Cancer With Severe Smoking

Status Recruiting

Clinical Trial Summary

Based on the previous work of LDCT screening, in order to improve the screening rate of central lung cancer for LDCT negative and severe smokers, the investigators plan to conduct China's first large-scale fluorescent bronchoscopy screening test.

Clinical Trial Description

CT scan is a commonly used method for clinical screening for early lung cancer, but research shows that LDCT scan has a higher detection rate for peripheral lesions (often adenocarcinoma), and a lower detection rate for central lung cancer (mostly squamous cell carcinoma). Fluorescent bronchoscopy uses the principle of differentiating fluorescence in different tissues to distinguish normal parts from diseased parts. It is often used for screening of central early lung cancer.Based on the results of the investigator's previous research, the investigators plan to conduct a second round of community screening-bronchoscopy screening, and perform white light bronchoscopy and autofluorescence bronchoscopy screening for high-risk groups of lung cancer with heavy smoking (≥400 years) and no obvious lung nodules. ;

Related Conditions & MeSH terms

• Heavy Smoking
• Lung Neoplasms

• NCT number: NCT04413669
• Study type: Interventional
• Source: Shanghai Chest Hospital
• Contact: Jiayuan Sun, PhD
• Phone: 86-021-22200000
• Email: jysun1976@163.com
• Status: Recruiting
• Phase: N/A
• Start date: December 26, 2019
• Completion date: December 1, 2020